Abstract

Background

Dietary fiber is effective for colorectal cancer (CRC) treatment. Interleukin-6 (IL-6) and its adaptors are potential targets for CRC therapy. Butyrate, a metabolite of dietary fiber, is a new, highly safe type of targeted drug.

Methods

In this study, Cell Counting Kit-8 cell viability and wound healing assays, western blot analysis, immunofluorescence staining, and xenograft tumor mouse models were used to evaluate the anticancer effect of butyrate and its possible mechanism in vivo and in vitro.

Results

Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo. Furthermore, NaB reduced the gp130 protein level by regulating its degradation rate via targeting TRAF5.

Conclusions

The fiber metabolite butyrate inhibits CRC development by reducing gp130 via TRAF5.

Details

Title
The fiber metabolite butyrate reduces gp130 by targeting TRAF5 in colorectal cancer cells
Author
Yin, Yuan; Li, Bo; Kuang, Yanbin; Ni, Shuo; Zhuge, Aoxiang; Yang, Jing; Lv, Longxian; Gu, Silan; Ren, Yan; Li, Yating; Wang, Kaicen; Yang, Liya; Zhu, Xueling; Wu, Jingjing; Bian, Xiaoyuan; Li, Lanjuan  VIAFID ORCID Logo 
Pages
1-14
Section
Primary research
Publication year
2020
Publication date
2020
Publisher
BioMed Central
e-ISSN
14752867
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s12935-020-01305-9
ProQuest document ID
2414889892
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.